Pakistan approves Chinese Sinopharm COVID-19 vaccine for emergency use

The Drug Regulatory Authority Pakistan (DRAP) said the vaccine, manufactured by China National Pharmaceutical Group (SinoPharm), had been given emergency use approval (EUA).

Reuters
January 19, 2021 / 07:58 AM IST

Representative image: Reuters

Pakistan approved the Chinese Sinopharm COVID-19 vaccine for emergency use, a government statement said, two days after AstraZeneca's vaccine developed with Oxford University received a similar authorization.

The Drug Regulatory Authority Pakistan (DRAP) said the vaccine, manufactured by China National Pharmaceutical Group (SinoPharm), had been given emergency use approval (EUA).

Pakistan's health ministry has said the country was in process of speaking to different vaccine makers.

"The two COVID-19 vaccines have been granted EUA with certain conditions," a DRAP's spokesman said, adding that both vaccines have been evaluated for their safety and quality.

The authorization will be reviewed on quarterly basis for further data regarding safety, efficacy and quality, the spokesman said.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Pakistan has been engaging with a number of vaccine makers, health minister Faisal Sultan said over the weekend, adding that the country could get "in the range of tens of millions" of vaccine doses under an agreement with China's Cansino Biologics Inc.

The vaccine company's Ad5-nCoV COVID-19 candidate is nearing completion of Phase III clinical trials in Pakistan. The preliminary results of the Cansino vaccine may come in by mid-February, Sultan said.

However, Pakistan has yet to place an order to procure any vaccine.

The minister said Pakistan planned to cover vaccines for the majority of the population for free, adding that private companies could also be allowed to import and sell vaccines once supply was available to an authorized company.

Pakistan reported 1,920 new coronavirus infections and 46 deaths on Monday, taking the total number of cases to more than 521,212 with fatalities approaching 11,000.
Reuters
TAGS: #coronavirus #World News
first published: Jan 19, 2021 07:43 am